PROVIDENCE, R.I. (WPRI) — Advancements in a drug targeting breast cancer growth have oncologists hopeful about potential treatment options for patients with advanced forms of the disease. Results from the DESTINY-Breast04 Phase III trial showed the intravenous drug Enhertu, also known as trastuzumab deruxtecan, demonstrated “superior and clinically meaningful” progression-free and […]
Saturday, Oct 8, 2022
Breaking News